C4 Therapeutics is a clinical-stage biopharmaceutical company focused on advancing targeted protein degradation science to develop a new generation of small-molecule medicines to transform how disease is treated. Co.'s primary advanced product candidate, CFT7455, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3 in clinical development for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. Co. is also developing CFT8634, an orally bioavailable Bifunctional Degradation Activating Compounds degrader of a protein target called BRD9, for synovial sarcoma and SMARCB1-deleted solid tumors. The CCCC YTD return is shown above.
The YTD Return on the CCCC YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether CCCC YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the CCCC YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|